Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

Abstract

PURPOSE The proteasome inhibitor bortezomib may enhance activity of chemoimmunotherapy in lymphoma. We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). PATIENTS AND METHODS Seventy-six… (More)
DOI: 10.1200/JCO.2010.31.1142

Topics

Cite this paper

@article{Ruan2011BortezomibPC, title={Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.}, author={Jia Ruan and Peter Martin and Richard R. Furman and Shing M Lee and K. L. Cheung and Julie Marie Vose and Ann S Lacasce and Julia Morrison and Rebecca L Elstrom and Scott Ely and Amy Chadburn and Ethel Cesarman and Morton Coleman and John P. Leonard}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2011}, volume={29 6}, pages={690-7} }